NATCO Pharma submitted an Abbreviated New Drug Application (ANDA) for a generic version of TABRECTA (Capmatinib hydrochloride) and believes it is the first to file this ANDA, expecting 180 days of marketing exclusivity; the original product had sales of USD 126 million in 2023.